京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002020 京新药业

已收盘 07-03 15:00:00

{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":15.19,"timestamp":1783062201000,"preClose":14.66,"halted":0,"volume":63056828,"delay":0,"changeRate":0.0362,"floatShares":724000000,"shares":861000000,"eps":0.8826,"marketStatus":"已收盘","change":0.53,"latestTime":"07-03 15:00:00","open":15.46,"high":15.47,"low":14.28,"amount":936000000,"amplitude":0.0812,"askPrice":15.19,"askSize":584,"bidPrice":15.18,"bidSize":2744,"shortable":0,"etf":0,"ttmEps":0.8826,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"adjPreClose":14.66,"symbolType":"stock","openAndCloseTimeList":[[1783042200000,1783049400000],[1783054800000,1783062000000]],"highLimit":16.13,"lowLimit":13.19,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"isCdr":false,"pbRate":2.07,"roa":"--","peRate":17.210514,"roe":"2.76%","epsLYR":0.92,"committee":0.394069,"marketValue":13079000000,"turnoverRate":0.0871,"status":0,"floatMarketCap":10997000000},"requestUrl":"/m/hq/s/002020/tweets","defaultTab":"tweets","newsList":[{"id":"2649048615","title":"股市必读：京新药业（002020）登7月3日交易所龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2649048615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649048615?lang=zh_cn&edition=full","pubTime":"2026-07-06 01:02","pubTimestamp":1783270936,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，京新药业报收于15.19元，上涨3.62%，换手率8.71%，成交量63.06万手，成交额9.36亿元。龙虎榜上榜京新药业因连续三个交易日内涨幅偏离值累计达20%，于2026年7月3日登上沪深交易所龙虎榜；此次为近5个交易日内第1次上榜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600000350.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648685507","title":"京新药业（002020）披露关于回购公司股份用于注销并减少注册资本的议案，7月2日股价上涨9.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648685507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648685507?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:20","pubTimestamp":1783002027,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，京新药业报收于14.66元，较前一交易日上涨9.98%，最新总市值为126.23亿元。近日，浙江京新药业股份有限公司发布《关于召开公司2026年第二次临时股东会的通知》。会议审议事项为关于回购公司股份用于注销并减少注册资本的议案，该议案为特别决议事项，需经出席会议股东所持表决权的三分之二以上通过。公司将对中小投资者的表决单独计票并披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648551112","title":"京新药业最新公告：获得盐酸卡立哌嗪胶囊药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2648551112","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648551112?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:50","pubTimestamp":1782899421,"startTime":"0","endTime":"0","summary":"京新药业(002020.SZ)公告称，公司收到国家药监局核准签发的盐酸卡立哌嗪胶囊《药品注册证书》，规格为1.5mg和3mg，用于治疗成人精神分裂症，为国内首家上市。该药品为非典型抗精神病药物，有助于提升公司精神神经领域竞争力，但对当期业绩无重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100034669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648165935","title":"7月1日京新药业涨6.73%，兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648165935","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648165935?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:45","pubTimestamp":1782895554,"startTime":"0","endTime":"0","summary":"证券之星消息，7月1日京新药业涨6.73%，收盘报13.33元，换手率3.85%，成交量27.88万手，成交额3.59亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。兴业医疗保健混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648281565","title":"股市必读：京新药业（002020）6月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2648281565","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648281565?lang=zh_cn&edition=full","pubTime":"2026-07-01 01:51","pubTimestamp":1782841872,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，京新药业报收于12.49元，下跌1.11%，换手率2.52%，成交量18.23万手，成交额2.29亿元。董秘最新回复投资者： 请问回复中提到近期完成11502项目的验收，请问为何在近期所有报表中都不提及，包括年报和港股上市申请书。三期临床有计划么董秘： 您好！管理层对此有何回应董秘： 您好！当日关注点交易信息汇总：6月30日主力资金净流入2058.48万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100001047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647110536","title":"京新药业：公司盐酸卡立哌嗪的审批正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2647110536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647110536?lang=zh_cn&edition=full","pubTime":"2026-06-30 16:45","pubTimestamp":1782809120,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司盐酸卡立哌嗪完成技术审评多长时间了？行政审批应该也完成了吧？京新药业回复：您好！公司盐酸卡立哌嗪的审批正常推进中。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000030199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647632216","title":"6月29日京新药业涨7.22%，兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647632216","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647632216?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:49","pubTimestamp":1782722993,"startTime":"0","endTime":"0","summary":"证券之星消息，6月29日京新药业涨7.22%，收盘报12.63元，换手率3.45%，成交量24.98万手，成交额3.08亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。兴业医疗保健混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647221863","title":"京新药业涨7.22%，开源证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2647221863","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647221863?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:49","pubTimestamp":1782722979,"startTime":"0","endTime":"0","summary":"今日京新药业涨7.22%，收盘报12.63元。2026年4月28日，开源证券研究员余汝意,刘艺发布了对京新药业的研报《公司信息更新报告：地达西尼快速放量，创新管线持续推进》，该研报对京新药业给出“买入”评级。京新药业个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900024792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646358843","title":"6月26日京新药业跌6.06%，兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646358843","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646358843?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:48","pubTimestamp":1782463701,"startTime":"0","endTime":"0","summary":"证券之星消息，6月26日京新药业跌6.06%，收盘报11.78元，换手率2.22%，成交量16.06万手，成交额1.93亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。兴业医疗保健混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600030500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645899015","title":"京新药业最新公告：董事长提议1亿至2亿元回购股份用于注销","url":"https://stock-news.laohu8.com/highlight/detail?id=2645899015","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645899015?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:48","pubTimestamp":1782294480,"startTime":"0","endTime":"0","summary":"京新药业(002020.SZ)公告称，公司实际控制人、董事长吕钢提议公司以集中竞价方式回购部分股份，用于注销并减少注册资本。回购资金总额不低于1亿元且不超过2亿元，回购价格上限不高于董事会审议通过回购决议前三十个交易日股票交易均价的150%，回购期限自股东会审议通过之日起不超过12个月。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400033109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643783388","title":"股市必读：京新药业（002020）6月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2643783388","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643783388?lang=zh_cn&edition=full","pubTime":"2026-06-16 03:12","pubTimestamp":1781550735,"startTime":"0","endTime":"0","summary":"截至2026年6月15日收盘，京新药业报收于12.39元，下跌0.16%，换手率1.3%，成交量9.43万手，成交额1.17亿元。公司的1类新药地达西尼获批后，在2024年年底成功进入医保目录。盐酸卡立哌嗪尚在审批注册流程，若顺利获批上市，公司会积极推进其销售工作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600002153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643279808","title":"京新药业：盐酸卡立哌嗪尚在审批注册流程","url":"https://stock-news.laohu8.com/highlight/detail?id=2643279808","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643279808?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:42","pubTimestamp":1781512943,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月15日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司重磅准创新药盐酸卡立哌嗪目前巳移出审评任务序列，进入行政审批和制证过程了吧？做为大单品业内人士普遍预估全国销售峰值近50亿，而公司独享近3年的独占期，公司预期销售额能达20亿吗？京新药业回复：您好！盐酸卡立哌嗪尚在审批注册流程，若顺利获批上市，公司会积极推进其销售工作。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500020130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642971458","title":"京新药业：目前中药创新药在公司管线中并非主要产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2642971458","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642971458?lang=zh_cn&edition=full","pubTime":"2026-06-09 08:48","pubTimestamp":1780966092,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月09日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司未来有考虑进军中药创新药的行列吗？我认为贵公司是好公司，至少不会虚无缥缈得和投资者讲故事，是愿意实打实的做好企业的发展，希望以后原研工作，从研发、审批、销售中都有好产品担当，打造良好的产品产业梯队体系，谢谢京新药业回复：您好！目前中药创新药在公司管线中并非主要产品。谢谢您对公司的关注和认可，公司会踏实做好经营工作，积极推进创新转型。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900006078.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1161","06978","002020","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642458972","title":"京新药业：地达西尼的销售工作在正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2642458972","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642458972?lang=zh_cn&edition=full","pubTime":"2026-06-09 08:48","pubTimestamp":1780966091,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月09日在投资者关系平台上答复投资者关心的问题。投资者提问：问公司创新药地达西尼日前互动平台上说无论同比还是环比都有较快增长，去年四季度大约7千多万，今年截止5月底，销售额达到2亿左右了吗？京新药业回复：您好！地达西尼的销售工作在正常推进中，作为公司第一个创新药，公司会努力做好商业化工作，具体销售情况敬请关注定期报告。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900006077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641483951","title":"京新药业最新公告：副总裁王军民辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2641483951","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641483951?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:01","pubTimestamp":1780912896,"startTime":"0","endTime":"0","summary":"京新药业(002020.SZ)公告称，王军民因个人原因申请辞去副总裁职务，王军民辞职后将不再在公司担任任何职务。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800024886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640497721","title":"京新药业：盐酸卡立哌嗪的审评工作在正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2640497721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640497721?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:58","pubTimestamp":1780477082,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：问吕董，公司盐酸卡立哌嗪到底申核到什么情况？公司新药B业务为什么推进如此之慢（同比同类公司简直是无法形容），什么原因？为什么公司不换谈判代表！京新药业回复：您好！盐酸卡立哌嗪的审评工作在正常推进中。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300034055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640704977","title":"京新药业：公司JX2201降脂新药临床I期结果良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2640704977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640704977?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:54","pubTimestamp":1780476867,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业(002020)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：吕董，我问降脂创新药完成一期临床，结果或疗效如何，比预期效果更好吗？没问现在正开展二期临床！请具体回复！！京新药业回复：您好！公司JX2201降脂新药临床I期结果良好，故而公司积极推进临床II期，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640294977","title":"京新药业：深圳巨烽主要是提供医用显示模块解决方案的","url":"https://stock-news.laohu8.com/highlight/detail?id=2640294977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640294977?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:54","pubTimestamp":1780476866,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：公司吕董，公司收购2家百年老字号及全国医疗显示器龙头深圳巨烽，当时的目的是什么？正常话仅深圳巨烽如果正常推动上市，估值应该也快百亿了吧？谢谢您的建议，深圳巨烽主要是提供医用显示模块解决方案的，目前经营正常推进，也在不断增加市场占有率，希望未来有合适的机会独立发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640280409","title":"股市必读：京新药业（002020）今年截至6月2日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640280409","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640280409?lang=zh_cn&edition=full","pubTime":"2026-06-03 03:26","pubTimestamp":1780428367,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，京新药业报收于13.12元，下跌2.6%，换手率1.41%，成交量10.21万手，成交额1.35亿元。当日关注点来自交易信息汇总：京新药业6月2日收盘跌2.6%，报13.12元，主力资金当日净流出233.47万元，前10个交易日累计净流出超2100万元。交易信息汇总股价提醒6月2日京新药业收盘报13.12元，跌2.6%，当日成交1.35亿元。根据收盘数据统计，该股当年累计跌幅25.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300005932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640798559","title":"股市必读：京新药业（002020）5月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640798559","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640798559?lang=zh_cn&edition=full","pubTime":"2026-06-01 03:06","pubTimestamp":1780254374,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，京新药业报收于13.44元，上涨1.66%，换手率1.85%，成交量13.41万手，成交额1.79亿元。董秘最新回复投资者： 问吕董，公司在业绩说明会上承诺核实公司二级市场是否被部分股东恶意对倒控制情况，问到底核实了吗？当日关注点来自交易信息汇总：5月29日主力资金净流入833.34万元，占总成交额4.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100001315.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783289845051,"stockEarnings":[{"period":"1week","weight":0.2895},{"period":"1month","weight":0.2105},{"period":"3month","weight":-0.0497},{"period":"6month","weight":-0.1779},{"period":"1year","weight":0.1498},{"period":"ytd","weight":-0.1779}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0421},{"period":"6month","weight":0.0188},{"period":"1year","weight":0.1683},{"period":"ytd","weight":0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31813人(较上一季度减少79.43%)","perCapita":"0股","listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","registeredCapital":"86102万元","survey":"　　浙江京新药业股份有限公司的主营业务是化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品是化学制剂、中成药、生物制剂、化学原料药、医疗器械。公司是第一批“中国医药企业制剂国际化先导企业”，连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。","listedPrice":10.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}